Figure 3.

The effect of RTKIs on VEGF₁₆₅a concentration–response curves. VEGFR2 NFAT cells were treated with (A) pazopanib, (B) vandetanib, (C) cediranib or (D) sorafenib for 1 h prior to the addition of increasing concentrations of VEGF₁₆₅a. Data are mean ± SEM of five (A and B), six (C) or seven (D) replicate experiments. Each individual experiment was performed in quadruplicate. Global analysis of the combined data presented for each RTKI (A–D; extra sum of squares F-test) indicated that there was only a significant difference in the EC₅₀ values for cetiranib (P < 0.05). In contrast, there was a significant decrease in E_max with all four RTKIs (P < 0001; Figure 3; extra sum of squares F-test).